Editas Medicine, Inc. (NASDAQ:EDIT)
Industry: Biotechnology

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Current Quote*
Last: $3.055
Change: 0.000
Book: $1.502
Volume: 2,413,044

As Of: 07/10 16:13 ET
*Quotes delayed by 20min.

Graphs for EDIT


3 Month Graph


6 Month Graph


1 Year Graph